Related Experiment Video
Updated: May 6, 2026
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer
11] Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA [2].
Abstract:
Small cell lung cancer (SCLC) at advanced stage is considered an incurable disease. Despite good response to initial chemotherapy, the responses in SCLC patients with metastatic disease are of short duration and resistance inevitably occurs. Although several target-specific drugs have altered the paradigm of treatment for many other cancers, we have yet to witness a revolution of the same magnitude in SCLC treatment. Anthracyclines, such as doxorubicin, have definite activity in this disease, and ganetespib has shown promising activity in preclinical models but underwhelming activity as a single agent in SCLC patients. Using SCLC cell lines, we demonstrated that ganetespib (IC50: 31 nM) was much more potent than 17-allylamino-17-demethoxygeldanamycin (17-AAG), a geldanamycin derivative (IC50: 16 microM). Ganetespib inhibited SCLC cell growth via induction of persistent G2/M arrest and Caspase 3-dependent cell death. MTS assay revealed that ganetespib synergized with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemotherapy. Expression of receptor-interacting serine/threonine-protein kinase 1 (RIP1), a protein that may function as a pro-survival scaffold protein or a pro-death kinase in TNFR1-activated cells, was induced by doxorubicin and downregulated by ganetespib. Depletion of RIP1 by either RIP1 small interfering RNA (siRNA) or ganetespib sensitized doxorubicin-induced cell death, suggesting that RIP1 may promote survival in doxorubicin-treated cells and that ganetespib may synergize with doxorubicin in part through the downregulation of RIP1. In comparison to ganetespib or doxorubicin alone, the ganetespib+doxorubicin combination caused significantly more growth regression and death of human SCLC xenografts in immunocompromised mice. We conclude that ganetespib and doxorubicin combination exhibits significant synergy and is efficacious in inhibiting SCLC growth in vitro and in mouse xenograft models. Our preclinical study suggests that ganetespib and doxorubicin combination therapy may be an effective strategy for SCLC treatment, which warrants clinical testing.
Insights
This study shows that combining ganetespib with doxorubicin effectively inhibits small cell lung cancer (SCLC) growth in preclinical models. This combination therapy, targeting SCLC, offers a promising new treatment strategy for this incurable disease.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Advanced stage small cell lung cancer (SCLC) remains largely incurable, with initial chemotherapy responses being short-lived due to inevitable resistance.
- While targeted therapies have advanced other cancers, SCLC treatment has seen limited progress.
- Ganetespib shows preclinical promise but limited single-agent activity in SCLC.
Purpose of the Study:
- To investigate the synergistic potential of ganetespib in combination with standard SCLC chemotherapeutics, specifically doxorubicin and etoposide.
- To elucidate the underlying mechanisms of ganetespib's activity and its interaction with doxorubicin, focusing on receptor-interacting serine/threonine-protein kinase 1 (RIP1).
Main Methods:
- Utilized SCLC cell lines to assess ganetespib's potency and its effects on cell cycle arrest and apoptosis.
- Conducted synergy assays (MTS assay) combining ganetespib with doxorubicin and etoposide.
- Investigated the role of receptor-interacting serine/threonine-protein kinase 1 (RIP1) by using small interfering RNA (siRNA) and assessing its expression levels.
- Evaluated the combination therapy in human SCLC xenograft models in immunocompromised mice.
Main Results:
- Ganetespib demonstrated significantly higher potency (IC50: 31 nM) than 17-AAG (IC50: 16 µM) in SCLC cell lines, inducing G2/M arrest and Caspase 3-dependent cell death.
- Ganetespib synergized with both doxorubicin and etoposide in inhibiting SCLC cell growth.
- Doxorubicin induced RIP1 expression, while ganetespib downregulated it. RIP1 depletion sensitized cells to doxorubicin-induced death, suggesting RIP1 promotes survival.
- The ganetespib+doxorubicin combination significantly inhibited SCLC xenograft growth and induced regression compared to single agents.
Conclusions:
- Ganetespib and doxorubicin exhibit significant synergy and potent anti-SCLC activity in vitro and in vivo.
- The combination therapy may work partly through ganetespib's downregulation of RIP1, a pro-survival protein in doxorubicin-treated cells.
- This preclinical data supports the ganetespib and doxorubicin combination as a promising therapeutic strategy for SCLC, warranting clinical investigation.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...